Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities
Pharmacological Research · 2023-08 · 194 · 106844
DOI: 10.1016/j.phrs.2023.106844 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacological Research, 2023-08. Verfasst von Lin Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Meteorological Sciences, National Natural Science Foundation of China, Cancer Foundation of China.
Abstract (Originalsprache)
Small-cell lung cancer (SCLC) is generally considered a 'homogenous' disease, with little documented inter-tumor heterogeneity in treatment guidance or prognosis evaluation. The precise identification of clinically relevant molecular subtypes remains incomplete and their translation into clinical practice is limited. In this retrospective cohort study, we comprehensively characterized the immune microenvironment in SCLC by integrating transcriptional and protein profiling of formalin-fixation-and-paraffin-embedded (FFPE) samples from 29 patients. We identified two distinct disease subtypes: immune-enriched (IE-subtype) and immune-deprived (ID-subtype), displaying heterogeneity in immunological, biological, and clinical features. The IE-subtype was characterized by abundant immune infiltrate and elevated levels of interferon-alpha/gamma (IFNα/IFNγ) and inflammatory response, while the ID-subtype featured a complete lack of immune infiltration and a more proliferative phenotype. These two immune subtypes are associated with clinical benefits in SCLC patients treated with adjuvant therapy, with the IE-subtype exhibiting a more favorable response leading to improved survival and reduced disease recurrence risk. Additionally, we identified and validated a personalized prognosticator of immunophenotyping, the CCL5/CXCL9 chemokine index (CCI), using machine learning. The CCI demonstrated superior predictive abilities for prognosis and clinical benefits in SCLC patients, validated in our institute immunohistochemistry cohort and multicenter bulk transcriptomic data cohorts. In conclusion, our study provides a comprehensive and multi-dimensional characterization of the immune architecture of SCLC using clinical FFPE samples and proposes a new immune subtyping conceptual framework enabling risk stratification and the appropriate selection of individualized therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China.
- School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, PR China.
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China.
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China. Electr…
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China. Electronic ad…
- School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, PR China. Electronic address: zhoumeng@wmu.edu.cn.
Förderung
- Chinese Academy of Meteorological Sciences
- National Natural Science Foundation of China
- Cancer Foundation of China
- Chinese Academy of Medical Sciences
Zitieren
APA
Yang, L., Zhang, Z., Dong, J., Zhang, Y., Yang, Z., Guo, Y., Sun, X., Li, J., Xing, P., Ying, J., & Zhou, M. (2023). Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities. Pharmacological Research, 194, 106844. https://doi.org/10.1016/j.phrs.2023.106844
Vancouver
Yang L, Zhang Z, Dong J, Zhang Y, Yang Z, Guo Y, et al. Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities. Pharmacological Research. 2023;194:106844. doi:10.1016/j.phrs.2023.106844
BibTeX
@article{Yang2023,
author = {Yang, Lin and Zhang, Zicheng and Dong, Jiyan and Zhang, Yibo and Yang, Zijian and Guo, Yiying and Sun, Xujie and Li, Junling and Xing, Puyuan and Ying, Jianming and Zhou, Meng},
title = {Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities},
journal = {Pharmacological Research},
year = {2023},
volume = {194},
pages = {106844},
doi = {10.1016/j.phrs.2023.106844}
}
EUVIMED